The Technology
Heart failure and fibrosis represent significant unmet medical needs, with current treatments often limited in effectiveness and long-term management. This innovative technology leverages cytokine-mediated immunomodulation, using a proprietary combination of cytokines to treat cardiac dysfunction and fibrosis. This therapeutic strategy originated from findings that tumor-bearing hosts exhibited improved cardiac function and reduced fibrosis due to systemic cytokine responses. Experimental data has confirmed that direct cytokine injections replicate and sustain these beneficial effects across various disease models, including Duchenne Muscular Dystrophy (DMD) and pressure-overload-induced heart failure.
A single administration of three purified cytokines significantly improves cardiac contractility, reduces fibrotic progression, and supports sustained therapeutic outcomes. Importantly, pre-clinical studies have shown that very low and safe doses of these cytokines are sufficient to achieve long-term therapeutic effects. Notably, these cytokines can be administered as recombinant, cell-free preparations, simplifying delivery and enhancing therapeutic consistency.
Advantages
- Rapid and sustained improvement in cardiac contractility
- Suppression of de novo synthesis as well as dissolution of existing fibrosis
- Proven efficacy across multiple preclinical disease models
- Single injection of low and safe dosage achieving long-term effects
- Potential to significantly delay or reverse disease progression
Applications and Opportunities
- Treatment of chronic heart failure and cardiac fibrosis
- Therapeutic management of Duchenne Muscular Dystrophy (DMD)
- Broader application in inflammatory and fibrotic conditions, including liver, lung, muscle, and gastrointestinal fibrosis
Business Development Contacts